Back to results
US 2013/0210831 A1Published application
Pyrrolopyrimidine compounds and uses thereof
AssigneeHutchison Medipharma Limited
InventorsWei-Guo Su, Wei Deng, Jinshui Li, Jianguo Ji
Life of this patent
Estimating the term…
Abstract
The present disclosure provides pyrrolopyrimidine compounds and methods of use therefor. For example, the disclosure provides certain pyrrolopyrimidine compounds capable of inhibiting JAK kinases. The disclosure further provides the pharmaceutical compositions containing these pyrrolopyrimidine compounds, and use of these pyrrolopyrimidine compounds in the treatment of disorders or diseases, such as inflammatory diseases and cancer.
Claims30
A compound of formula (I):
- wherein
- R1 is chosen from hydrogen, alkyl, cycloalkyl and heterocycle,
- R2 is chosen from aryl, heterocycle, heteroaryl, —C(O)NRcRd, —S(O)nRf, and —S(O)nNRcRd, or R1 and R2, together with the N atom to which they are attached, form an optionally substituted 3- to 7-membered ring, which optionally comprises one or two additional heteroatoms and which is further optionally fused to an optionally substituted heteroaryl or optionally substituted aryl ring;
- and each of the above said alkyl, aryl, cycloalkyl, heterocycle, heteroaryl in R1 and R2 is optionally substituted with one or more groups chosen from optionally substituted lower alkyl, optionally substituted aryl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, —C(O)Ra, —C(O)ORb, —CN, —C(O)NRcRd, halo, optionally substituted haloalkyl, optionally substituted heterocycle, optionally substituted heteroaryl, —NRcRd, —NReC(O)Ra, —NReC(O)ORb, —NReC(O)NRcRd, —NReS(O)nRf, —NReS(O)nNRcRd, —NO2, —ORb, —S(O)nRf, and —S(O)nNRcRd;
- m and n are independently chosen from 0, 1, and 2;
- for each occurrence, Ra, Rb, Rc, Rd, Re and Rf are each independently chosen from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted haloalkyl, optionally substituted heteroaryl and optionally substituted heterocycle,
- or Rc and Rd, with the nitrogen to which they are attached, combine to form a heterocycle ring, which is optionally substituted with one or more groups chosen from halo, lower alkyl, hydroxy, and lower alkoxy, wherein the heterocycle ring further optionally comprises one or two additional heteroatoms chosen from N, O and S;
- or at least one pharmaceutically acceptable salt thereof.
5 more elements
A compound chosen from compounds 1 to 260 and/or at least one pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.